Clinical trials: Brain Tumor, Recurrent
Pediatric Brain Tumor
Integrated PET/MRI and Germline Variants to Differentiate Brain Tumopr Recurrence From Iatrogenicchanges in Children
Nuclear magnetic resonance imaging (NMR) is used in pediatric brain tumors for purposes of diagnosis, evaluation of response to treatments, and monitoring of patients in follow-up.
- Trial name
- NCT06226519
- Testing
- 11C-MET-PET/RMN
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Pituitary Adenoma 1, Acth-Secreting
Pituitary Adenoma and Serum Lipid
Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu.
- Trial name
- NCT04021212
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Shandong Provincial Hospital
Brain and Central Nervous System Tumors
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have…
- Trial name
- NCT00004937
- Testing
- acridine carboxamide
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01390571
- Testing
- olaparib, temozolomide, gene expression analysis
- Where
- 7 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Cancer Research UK
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Glioblastoma, Adult Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00433381
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 93 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014105
- Testing
- carboplatin, temozolomide
- Where
- United States
- Sponsor
- Atlantic Health System
Brain and Central Nervous System Tumors
Biological Therapy in Treating Patients With Primary or Advanced Glioma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or…
- Trial name
- NCT00003067
- Testing
- aldesleukin, lymphokine-activated killer cells
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Glioma
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Gliomas are the most common type of primary brain tumors, with the main treatment modalities including surgery, radiotherapy, and chemotherapy.
- Trial name
- NCT06818331
- Testing
- SMES+PTX, Paclitaxel, Specific mode electroacupuncture stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Central Nervous System Tumor, Pediatric, Glioma
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells that are lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and…
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma
- Trial name
- NCT03638167
- Testing
- EGFR806-specific chimeric antigen receptor (CAR) T cell
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Seattle Children's Hospital
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.
- Trial name
- NCT01898130
- Testing
- bevacizumab, quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Recurrent Glioblastoma
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
- Trial name
- ASPIRE (NCT06389591)
- Testing
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Astrocytic Tumor, Oligodendroglial Tumor
Study of How Safe and Effective Tarlatamab is in Brain Cancers
This is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.
- Trial name
- NCT06776250
- Testing
- Tarlatamab
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University Health Network, Toronto
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Brain and Central Nervous System Tumors
Gene Therapy in Treating Patients With Primary Brain Tumors
RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir.
- Trial name
- NCT00002824
- Testing
- gene therapy, chemotherapy, ganciclovir
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Cancer
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide and vinorelbine in treating patients who…
- Trial name
- NCT00026494
- Testing
- temozolomide, vinorelbine tartrate
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
This phase I trial is studying the side effects and best dose of aminolevulinic acid during surgery in treating patients with malignant brain tumors.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01148966
- Testing
- aminolevulinic acid, laboratory biomarker analysis, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Brain Metastases, Lung Cancer
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab.
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma
- Trial name
- NCT01386580
- Testing
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 84 people
- Sponsor
- BBB-Therapeutics B.V.
Non Small Cell Lung Cancer, Brain Metastases, Adult
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
This is an open-label, non-randomised, phase II, multicenter clinical trial. 71 stage IV or recurrent, non-small cell lung cancer patients with synchronous brain metastases will be enrolled in this trial to evaluate the efficacy…
- Conditions
- Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer
- Trial name
- NIVIPI-Brain (NCT05012254)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 18 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Fundación GECP